Predictors of portal vein thrombosis after splenectomy in patients with cirrhosis

Table 1 Demonthsgraphic and clinical characteristics of the study population at baseline

Variables	Data
Gender
Men, n (%)	21 (46.7)
Female, n (%)	24 (53.3)
Age (yr)	47.62 ± 11.16
Etiology
HBV, n (%)	37 (74.0)
HCV, n (%)	2 (4.0)
AIH, n (%)	4 (8.0)
Unexplained cirrhosis, n (%)	2 (4.0)
WBC (109/L)	2.21 ± 1.18
RBC (1012/L)	3.68 ± 0.78
PLT (109/L)	44.09 ± 28.54
AST (U/L)	35.18 ± 14.82
ALT (U/L)	26.89 ± 14.30
TBIL (μmol/L)	26.77 ± 15.97
ALB (g/L)	38.81 ± 4.16
INR	1.30 ± 0.19
PT (s)	14.23 ± 1.94
PTA (%)	68.71 ± 13.45
D-D2 (mg/L)	0.56 ± 1.03
MELD	10.76 ± 3.30
PVD (mm)	13.66 ± 2.49
PV (cm/s)	19.87 ± 5.88
SVD (mm)	10.35 ± 2.61
Ascites, n (%)	19 (42.2)
Child-Pugh grade
A, n (%)	32 (71.1)
B, n (%)	13 (28.9)
C, n (%)	0 (0.0)
Operation ways	1.30 ± 0.19
Open splenectomy, n (%)	35 (78.8)
Laparoscopic splenectomy, n (%)	10 (21.2)
Spleen volume (cm3)	2349.28 (531.12-13080.00)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; AIH: Autoimmune hepatitis; WBC: White blood cell counts; RBC: Red blood cell counts; PLT: Platelet counts; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TBIL: Total bilirubin; ALB: Albumin; INR: International normalized ratio; PT: Prothrombin time; PTA: Prothrombin activity; MELD: Monthsdel for end-stage liver disease; PVD: Portal vein diameter; PV: Portal vein velocity; SVD: Splenic vein.